PMID- 30897713
OWN - NLM
STAT- MEDLINE
DCOM- 20190712
LR  - 20200225
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 20
IP  - 6
DP  - 2019 Mar 20
TI  - Antigen Targets for the Development of Immunotherapies in Leukemia.
LID - 10.3390/ijms20061397 [doi]
LID - 1397
AB  - Immunotherapeutic approaches, including allogeneic stem cell transplantation and 
      donor lymphocyte infusion, have significantly improved the prognosis of leukemia 
      patients. Further efforts are now focusing on the development of immunotherapies 
      that are able to target leukemic cells more specifically, comprising monoclonal 
      antibodies, chimeric antigen receptor (CAR) T cells, and dendritic cell- or 
      peptide-based vaccination strategies. One main prerequisite for such 
      antigen-specific approaches is the selection of suitable target structures on 
      leukemic cells. In general, the targets for anti-cancer immunotherapies can be 
      divided into two groups: (1) T-cell epitopes relying on the presentation of 
      peptides via human leukocyte antigen (HLA) molecules and (2) surface structures, 
      which are HLA-independently expressed on cancer cells. This review discusses the 
      most promising tumor antigens as well as the underlying discovery and selection 
      strategies for the development of anti-leukemia immunotherapies.
FAU - Bauer, Jens
AU  - Bauer J
AUID- ORCID: 0000-0003-3731-2385
AD  - Department of Hematology and Oncology, University Hospital Tubingen, 72076 
      Tubingen, Germany. j.bauer@uni-tuebingen.de.
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      72076 Tubingen, Germany. j.bauer@uni-tuebingen.de.
FAU - Nelde, Annika
AU  - Nelde A
AUID- ORCID: 0000-0001-8504-8481
AD  - Department of Hematology and Oncology, University Hospital Tubingen, 72076 
      Tubingen, Germany. annika.nelde@uni-tuebingen.de.
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      72076 Tubingen, Germany. annika.nelde@uni-tuebingen.de.
FAU - Bilich, Tatjana
AU  - Bilich T
AUID- ORCID: 0000-0002-8107-0419
AD  - Department of Hematology and Oncology, University Hospital Tubingen, 72076 
      Tubingen, Germany. tatjana.bilich@uni-tuebingen.de.
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      72076 Tubingen, Germany. tatjana.bilich@uni-tuebingen.de.
FAU - Walz, Juliane S
AU  - Walz JS
AD  - Department of Hematology and Oncology, University Hospital Tubingen, 72076 
      Tubingen, Germany. juliane.walz@med.uni-tuebingen.de.
LA  - eng
GR  - DFG STI 704/1-1/Deutsche Forschungsgemeinschaft/
GR  - Nr.2016.177.1/Wilhelm Sander-Stiftung/
PT  - Journal Article
PT  - Review
DEP - 20190320
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antigens)
RN  - 0 (Peptides)
SB  - IM
MH  - Antigens/*immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Leukemia/immunology/metabolism/*therapy
MH  - Peptides/immunology
MH  - T-Lymphocytes/immunology/metabolism
PMC - PMC6471800
OTO - NOTNLM
OT  - HLA
OT  - T cell
OT  - antigen
OT  - epitope
OT  - immunotherapy
OT  - leukemia
OT  - peptide
OT  - target
OT  - vaccination
COIS- The authors declare no conflict of interest.
EDAT- 2019/03/23 06:00
MHDA- 2019/07/13 06:00
PMCR- 2019/03/01
CRDT- 2019/03/23 06:00
PHST- 2019/02/26 00:00 [received]
PHST- 2019/03/15 00:00 [revised]
PHST- 2019/03/18 00:00 [accepted]
PHST- 2019/03/23 06:00 [entrez]
PHST- 2019/03/23 06:00 [pubmed]
PHST- 2019/07/13 06:00 [medline]
PHST- 2019/03/01 00:00 [pmc-release]
AID - ijms20061397 [pii]
AID - ijms-20-01397 [pii]
AID - 10.3390/ijms20061397 [doi]
PST - epublish
SO  - Int J Mol Sci. 2019 Mar 20;20(6):1397. doi: 10.3390/ijms20061397.